The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals.
DAAs
cascade of care
data linkage
hepatitis C
testing
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
11
03
2019
revised:
14
08
2019
accepted:
19
08
2019
pubmed:
25
8
2019
medline:
6
10
2020
entrez:
25
8
2019
Statut:
ppublish
Résumé
Population-level monitoring of hepatitis C virus (HCV) infected people across cascades of care identifies gaps in access and engagement in care and treatment. We characterized the population-level care cascade for HCV in British Columbia (BC), Canada before and after introduction of Direct Acting Antiviral (DAA) treatment. BC Hepatitis Testers Cohort (BC-HTC) includes 1.7 million individuals tested for HCV, HIV, reported cases of hepatitis B, and active tuberculosis in BC from 1990 to 2018 linked to medical visits, hospitalizations, cancers, prescription drugs and mortality data. We defined six HCV care cascade stages: (a) antibody diagnosed; (b) RNA tested; (c) RNA positive; (d) genotyped; (e) initiated treatment; and (f) achieved sustained virologic response (SVR). We estimated 61 127 people were HCV antibody positive in BC in 2018 (undiagnosed: 7686, 13%; diagnosed: 53 441, 87%). Of those diagnosed, 83% (44 507) had HCV RNA testing, and of those RNA positive, 90% (28 716) were genotyped. Of those genotyped, 61% (17 441) received therapy, with 90% (15 672) reaching SVR. Individuals from older birth cohorts had lower progression to HCV RNA testing. While people who currently inject drugs had the highest proportional progression to RNA testing, this group had the lowest proportional treatment uptake. Although gaps in HCV RNA and genotype testing after antibody diagnosis exist, the largest gap in the care cascade is treatment initiation, despite introduction of DAA treatment and removal of treatment eligibility restrictions. Further interventions are required to ensure testing and treatment is equitably accessible in BC.
Sections du résumé
BACKGROUND
Population-level monitoring of hepatitis C virus (HCV) infected people across cascades of care identifies gaps in access and engagement in care and treatment. We characterized the population-level care cascade for HCV in British Columbia (BC), Canada before and after introduction of Direct Acting Antiviral (DAA) treatment.
METHODS
BC Hepatitis Testers Cohort (BC-HTC) includes 1.7 million individuals tested for HCV, HIV, reported cases of hepatitis B, and active tuberculosis in BC from 1990 to 2018 linked to medical visits, hospitalizations, cancers, prescription drugs and mortality data. We defined six HCV care cascade stages: (a) antibody diagnosed; (b) RNA tested; (c) RNA positive; (d) genotyped; (e) initiated treatment; and (f) achieved sustained virologic response (SVR).
RESULTS
We estimated 61 127 people were HCV antibody positive in BC in 2018 (undiagnosed: 7686, 13%; diagnosed: 53 441, 87%). Of those diagnosed, 83% (44 507) had HCV RNA testing, and of those RNA positive, 90% (28 716) were genotyped. Of those genotyped, 61% (17 441) received therapy, with 90% (15 672) reaching SVR. Individuals from older birth cohorts had lower progression to HCV RNA testing. While people who currently inject drugs had the highest proportional progression to RNA testing, this group had the lowest proportional treatment uptake.
CONCLUSIONS
Although gaps in HCV RNA and genotype testing after antibody diagnosis exist, the largest gap in the care cascade is treatment initiation, despite introduction of DAA treatment and removal of treatment eligibility restrictions. Further interventions are required to ensure testing and treatment is equitably accessible in BC.
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2261-2272Subventions
Organisme : CIHR
ID : PHE-141773
Pays : Canada
Organisme : CIHR
ID : NHC - 142832
Pays : Canada
Organisme : CIHR
ID : PJT-156066
Pays : Canada
Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Blach S, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161-176.
Aspinall EJ, Hutchinson SJ, Janjua NZ, et al. Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment. J Hepatol. 2015;62(2):269-277.
Kuo M, Janjua NZ, Burchell AN, Buxton JA, Krajden M, Gilbert M. Decreasing hepatitis c incidence among a population with repeated tests: British Columbia, Canada, 1993-2011. Am J Public Health. 2015;105(8):1604-1610.
Iversen J, Wand H, Topp L, Kaldor J, Maher L. Reduction in HCV incidence among injection drug users attending needle and syringe programs in Australia: a linkage study. Am J Public Health. 2013;103(8):1436-1444.
Chan H, Chen CJ, Omede O, et al. The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4. J Viral Hepatitis. 2017;24(S2):25-43.
Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising mortality associated with hepatitis C virus in the United States, 2003-2013. Clin Infect Dis. 2016;62(10):1287-1288.
Janjua NZ, Yu A, Kuo M, et al. Twin epidemics of new and prevalent hepatitis C infections in Canada: BC Hepatitis Testers Cohort. BMC Infect Dis. 2016;16:334.
Janjua NZ, Islam N, Wong J, et al. Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study. J Viral Hepat. 2017;24(8):624-630.
Stephens DB, Young AM, Havens JR. Healthcare contact and treatment uptake following hepatitis C virus screening and counseling among rural Appalachian people who use drugs. Int J Drug Policy. 2017;47:86-94.
Janjua NZ, Chong M, Kuo M, et al. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. J Hepatol. 2016;66(3):504-513.
Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis. 2015;61(5):730-740.
McGowan CE, Fried MW. Barriers to hepatitis C treatment. Liver Int. 2012;32:151-156. https://doi.org/10.1111/j.1478-3231.2011.02706.x
Hajarizadeh B, Grebely J, McManus H, et al. Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment. J Gastroenterol Hepatol. 2017;32(1):229-236.
Kovari H, Ledergerber B, Cavassini M, et al. High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013. J Hepatol. 2015;63(3):573-580.
Wansom T, Falade-Nwulia O, Sutcliffe CG, et al. Barriers to hepatitis C virus (HCV) Treatment initiation in patients with human immunodeficiency virus/HCV coinfection: lessons from the interferon era. Open Forum Infect Dis. 2017;4(1):ofx024.
Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med. 2005;20(8):754-758.
WHO. Global health sector strategy on viral hepatitis 2016-2021. 2016.
Maier MM, Ross DB, Chartier M, Belperio PS, Backus LI. Cascade of care for hepatitis C virus infection within the US veterans health administration. Am J Public Health. 2016;106(2):353-358.
Cachay ER, Hill L, Wyles D, et al. The hepatitis C cascade of care among HIV infected patients: a call to address ongoing barriers to care. PLoS ONE. 2014;9(7):e102883.
Jonas MC, Rodriguez CV, Redd J, Sloane DA, Winston BJ, Loftus BC. Streamlining screening to treatment: the hepatitis c cascade of care at Kaiser Permanente Mid-Atlantic States. Clin Infect Dis. 2016;62(10):1290-1296.
Wade AJ, Macdonald DM, Doyle JS, et al. The cascade of care for an australian community-based hepatitis C treatment service. PLoS ONE. 2015;10(11):e0142770.
Young S, Wood E, Milloy M-J, et al. Hepatitis C cascade of care among people who inject drugs in Vancouver, Canada. Subst Abus. 2018;1-22.
Iversen J, Grebely J, Catlett B, Cunningham P, Dore GJ, Maher L. Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia. Int J Drug Policy. 2017;47:77-85.
Janjua NZ, Kuo M, Chong M, et al. Assessing hepatitis C burden and treatment effectiveness through the British Columbia Hepatitis Testers Cohort (BC-HTC): design and characteristics of linked and unlinked participants. PLoS ONE. 2016;11(3):e0150176.
Janjua NZ, Kuo M, Yu A, et al. The Population level cascade of care for hepatitis C in British Columbia, Canada: the BC Hepatitis Testers Cohort (BC-HTC). EBioMedicine. 2016;12:189-195.
Marshall AD, Saeed S, Barrett L, et al. Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. CMAJ Open. 2016;4(4):E605-E614.
Health BCMo.PharmaCare coverage of new direct-acting antiviral drugs and expanded coverage for adults with chronic hepatitis C infection. 2017.
Trubnikov M, Yan P, Njihia J, Archibald C. Identifying and describing a cohort effect in the national database of reported cases of hepatitis C virus infection in Canada (1991-2010): an age-period-cohort analysis. CMAJ Open. 2014;2(4):E281-287.
Wong W, Tu H-A, Feld JJ, Wong T, Krahn M. Cost-effectiveness of screening for hepatitis C in Canada. Can Med Assoc J. 2015;187(3):E110-E121.
Islam N, Krajden M, Gilbert M, et al. Role of primary T-cell immunodeficiency and hepatitis B coinfection on spontaneous clearance of hepatitis C: The BC Hepatitis Testers Cohort. J Viral Hepat. 2017;24(5):421-429.
Trubnikov M, Yan P, Archibald C. Estimated prevalence of Hepatitis C Virus infection in Canada, 2011. Can Commun Dis Rep. 2014;40(19):429-436.
Sokol R, Fisher E. Peer Support for the hardly reached: a systematic review. Am J Public Health. 2016;106(7):e1-8.
Hajarizadeh B, Grebely J, Matthews GV, Martinello M, Dore GJ. Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia. J Viral Hepatitis. 2018;25(6):640-648.
Chapko MK, Dufour DR, Hatia RI, Drobeniuc J, Ward JW, Teo C-G. Cost-effectiveness of strategies for testing current hepatitis C virus infection. Hepatology. 2015;62(5):1396-1404.
Lamoury F, Bajis S, Hajarizadeh B, et al. Evaluation of the Xpert HCV viral load finger-stick point-of-care assay. J Infect Dis. 2018;217(12):1889-1896.
Lamoury F, Hajarizadeh B, Soker A, et al. Evaluation of a hepatitis C virus core antigen assay in plasma and dried blood spot samples. J Mol Diagn. 2018;20(5):621-627.
Applegate TL, Fajardo E, Sacks JA. Hepatitis C virus diagnosis and the holy grail. Infect Dis Clin North Am. 2018;32(2):425-445.
Ford N, Swan T, Beyer P, Hirnschall G, Easterbrook P, Wiktor S. Simplification of antiviral hepatitis C virus therapy to support expanded access in resource-limited settings. J Hepatol. 2014;61(1, Supplement):S132-S138.
Lemoine M, Cooke GS. The Egyptian hepatitis C programme: a model of HCV treatment intervention? J Hepatol. 2018;68(4):638-639.
Cousien A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, Dhersin JS, Yazdanpanah Y. Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs. Hepatology. 2016;63(4):1090-1101.
Bajis S, Dore GJ, Hajarizadeh B, Cunningham EB, Maher L, Grebely J. Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: a systematic review. Int J Drug Policy. 2017;47:34-46.
Rossi C, Butt ZA, Wong S, et al. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort. J Hepatol. 2018;69(5):1007-1014.
Krajden M, Cook D, Janjua NZ. Contextualizing Canada’s hepatitis C virus epidemic. Canadian Liver Journal. 2018;1(4):218-230.
Islam N, Krajden M, Shoveller J, et al. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study. Lancet Gastroenterol Hepatol. 2017;2(3):200-210.
Grebely J, Lima VD, Marshall B, et al. Declining incidence of hepatitis C virus infection among people who inject drugs in a canadian setting, 1996-2012. PLoS ONE. 2014;9(6):e97726.
Yiqiao Li SW, Butt Z, Rossi C, et al. Hepatitis C incidence rate among people who inject drugs (PWID) in British Columbia from 2000 to 2015. Can Liver J. 2019;2(2):3-135.
Krajden M, Cook DA, Wong S, et al. What is killing people with hepatitis C virus infection? Analysis of a population-based cohort in Canada. Int J Drug Policy. 2019;72:114-122.
Janjua NZ, Islam N, Kuo M, et al. Identifying injection drug use and estimating population size of people who inject drugs using healthcare administrative datasets. Int J Drug Policy. 2018;55:31-39.